



Cigna Corporation (CI)

Updated February 13th, 2023 by Nathan Parsh

Key Metrics

Current Price:	\$299	5 Year CAGR Estimate:	12.7%	Market Cap:	\$91 billion
Fair Value Price:	\$320	5 Year Growth Estimate:	10.0%	Ex-Dividend Date:	03/07/2023
% Fair Value:	93%	5 Year Valuation Multiple Estimate:	1.4%	Dividend Payment Date:	03/21/2023
Dividend Yield:	1.6%	5 Year Price Target	\$515	Years Of Dividend Growth:	3
Dividend Risk Score:	B	Retirement Suitability Score:	C	Rating:	Buy

Overview & Current Events

Cigna is a leading provider of insurance products and services. The company's products include dental, medical, disability and life insurance that it provides through employer-sponsored, government-sponsored and individual coverage plans. Cigna operates four business segments, including Evernorth, which provides pharmacy services and benefit management, U.S. Medical, which provides commercial and government health insurance, International Markets and Group Disability. Evernorth contributes 70% of annual revenues while Cigna Healthcare accounts for 24%. Cigna has annual revenues of ~\$188 billion.

On February 3rd, 2023, Cigna announced that it was increasing its quarterly dividend 9.8% to \$1.23.

Also on February 3rd, 2023, Cigna reported fourth quarter and full year results for the period ending December 31st, 2022. For the quarter, revenue grew 0.2% to \$45.75 billion and was in-line with estimates. Adjusted earnings-per-share of \$4.96 compared to adjusted earnings-per-share of \$4.77 in the prior year and was \$0.09 better than expected. For the year, revenue grew 3.7% to \$180.5 billion while adjusted earnings-per-share of \$23.27 compared to \$20.47 in 2021.

For the quarter, total pharmacy customers were lower by 1.6% to 105.6 million. Total medical customers grew 5.4% year-over-year to just over 18 million. Adjusted revenue for the Evernorth segment, which is the largest within the company, increased 3.1% to \$36.2 billion due to organic growth in specialty pharmacy services. Adjusted revenue for Cigna Healthcare was down slightly to \$11.1 billion, largely due to the divested Medicaid business. Excluding this business, revenue was up 1%.

Cigna provided an outlook for 2023 as well. Revenue is expected to be least \$187 billion for the year. The company projects adjusted earnings-per-share of at least \$24.60. We have initiated our forecast accordingly.

Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
EPS	\$6.78	\$7.43	\$8.66	\$8.10	\$10.46	\$14.22	\$17.05	\$18.45	\$20.47	\$23.27	\$24.60	\$39.62
DPS	\$0.04	\$0.04	\$0.04	\$0.04	\$0.04	\$0.04	\$0.04	\$0.04	\$4.00	\$4.48	\$4.92	\$6.28
Shares¹	279	264	257	257	244	381	373	355	327	305	305	285

Earnings-per-share have a compound annual growth rate of 13.1% for the 2013 through 2022 period of time. An increase in the share count during this time hides the fact that net profit has actually increased at a rate of almost 16% per year. Cigna's growth rate has remained strong in the medium-term as earnings-per-share have a compound annual growth rate of 10.4% since 2018. One reason that earnings have a CAGR in the double-digit range is that the need for pharmacy services and health care plans will increase as more people age. Cigna's merger with Express Scripts, one of the top pharmacy benefit managers in the market, in 2018 should also provide business tailwinds. In addition, Cigna has an ambitious goal to reduce its health care costs, which, overall, have risen much higher than inflation. We reaffirm our targeted earnings-per-share growth rate of 10% through 2028 as we find Cigna's business model very attractive.

Cigna's dividend had never been a priority for the company. After cutting its dividend by 20% in 2009, the company has paid the same amount every year up until 2020. It should be noted that Cigna had typically paid an annual dividend in

¹ Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Cigna Corporation (CI)

Updated February 13th, 2023 by Nathan Parsh

April of each year. That all changed when the company declared a \$1.00 quarterly dividend for the March 25, 2021 payment date. The company followed that up with a double-digit increase in 2022. We now anticipate dividend growth of at least 5% annually through 2028.

Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/E	10.6	12.1	15.5	16.4	16.3	13.3	10.1	10.2	11.2	14.2	12.2	13.0
Avg. Yld.	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	1.7%	1.4%	1.6%	1.2%

Shares of Cigna have decreased \$26, or 8.0%, since our November 7th, 2022 report. The stock has an average price-to-earnings ratio of 13.0 over the last decade. Currently, the stock is valued at just over 12 times earnings estimates for the year. Price-to-earnings ratios were likely lower during the early portions of the past decade due to market concerns over how health care plans would do. Those fears appear to have abated somewhat. Reaching our 2028 target multiple of 13 times earnings could add 1.4% to annual returns over the next five years.

Cigna's dividend has largely not played a role in the company's total returns. That changed somewhat as Cigna's stock now offers a yield that is just below the average yield of the S&P 500 index.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	1%	1%	0%	0%	0%	0%	0%	0%	20%	19%	20%	16%


Cigna happens to operate in an industry that tends to hold up well during recessionary times as health insurance and pharmacy businesses are still in demand. Earnings-per-share fell from \$3.96 in 2007 to \$3.42 in 2008 (a 13.6% decrease), but rebounded to make a new high in 2009. Cigna has seen earnings-per-share grow each year thereafter outside of 2016.

We feel that Cigna has some immense competitive advantages. The company is one of the largest names in its industry, giving it a size and scale that is hard to match. Cigna's acquisition of Express Scripts appears to have been a solid move, strengthening the company's presence in its pharmacy business. Perhaps most important, an aging demographic will need increased pharmacy and medical services, giving Cigna an incredibly large pool of potential customers.

Final Thoughts & Recommendation

Cigna is now expected to produce total returns of 12.7% through 2028, up from our prior estimate of 9.4%. Our projected return stems from a 10% earnings growth rate, a starting yield of 1.6%, and a small tailwind from multiple expansion. Cigna continues to produce solid growth rates, something we expect to continue in 2023. Shares earn a buy rating due to projected returns.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Cigna Corporation (CI)

Updated February 13th, 2023 by Nathan Parsh

Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Revenue	29119	32380	34914	37876	40007	42043	48569	153743	160577	174272
SG&A Exp.					9790	10030	11934	14053	14072	13030
Depr. & Amor.	560	597	588	585	610	566	695	3651	2802	2923
Net Profit	1623	1476	2102	2094	1867	2237	2637	5104	8458	5365
Net Margin	5.6%	4.6%	6.0%	5.5%	4.7%	5.3%	5.4%	3.3%	5.3%	3.1%
Free Cash Flow	1942	192	1685	2423	3565	3615	3242	8435	9256	6037
Income Tax	853	698	1210	1250	1136	1374	935	1450	2379	1367

Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Assets	53734	54336	55870	57088	59360	61759	153226	155774	155451	154889
Cash & Equivalents	2978	2795	1420	1968	3185	2972	3855	4619	10182	5081
Acc. Receivable	8033	9290	9837	10507	9555	8667	15704	16003	17199	19639
Goodwill & Int.	7061	6931	6698	6587	6404	6509	83508	81164	79827	79913
Total Liabilities	43965	43755	45081	45044	45633	48048	112191	110430	105123	107705
Accounts Payable	8523	7506	8444	8848	8946	489	15068	15544	18825	6655
Long-Term Debt	5187	5247	5126	5169	5032	5439	42478	37407	32919	33670
Total Equity	9769	10567	10774	12035	13723	13711	41028	45338	50321	47112
LTD/E Ratio	0.53	0.50	0.48	0.43	0.37	0.40	1.04	0.83	0.65	0.71

Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Return on Assets	3.1%	2.7%	3.8%	3.7%	3.2%	3.7%	2.5%	3.3%	5.4%	3.5%
Return on Equity	18.3%	14.5%	19.7%	18.4%	14.5%	16.3%	9.6%	11.8%	17.7%	11.0%
ROIC	11.6%	9.6%	13.2%	12.6%	10.4%	11.8%	5.1%	6.1%	10.2%	6.5%
Shares Out.	285	279	264	257	257	244	381	373	355	327
Revenue/Share	100.57	113.74	129.98	145.35	154.08	164.83	196.91	408.98	439.96	515.66
FCF/Share	6.71	0.67	6.27	9.30	13.73	14.17	13.14	22.44	25.36	17.86

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.